TBPCOB | 1196074-50-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: TBPCOB
• 英文别名: (2S)-2-{[(6-tert-butylpyridin-3-yl)oxy]methyl}-2,3-dihydro[1,3]oxazolo[3,2-a]benzimidazole-7-carbonitrile；(2S)-2-[(6-tert-butylpyridin-3-yl)oxymethyl]-1,2-dihydro-[1,3]oxazolo[3,2-a]benzimidazole-6-carbonitrile
• CAS: 1196074-50-6
• 化学式: C₂₀H₂₀N₄O₂
• 分子量: 348.404
• InChiKey: WSBZWPGZGTWIJM-HNNXBMFYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  73
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  5-(苄氧基)-2-溴吡啶 在 20 % Pd(OH)2/C 偶氮二甲酸二异丙酯 、 氢气 、 copper(l) cyanide 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 为溶剂， 反应 54.33h， 生成 TBPCOB
  参考文献：
  名称：

  [EN] OXAZOLOBENZIMIDAZOLE DERIVATIVES
  [FR] DÉRIVÉS D'OXAZOLOBENZIMIDAZOLE

  摘要：

  本发明涉及噁唑基苯并咪唑衍生物，它们是代谢型谷氨酸受体的增强剂，特别是mGluR2受体，可用于治疗或预防与谷氨酸功能障碍相关的神经和精神疾病，以及代谢型谷氨酸受体参与的疾病。该发明还涉及包含这些化合物的药物组合物，以及在预防或治疗代谢型谷氨酸受体参与的这类疾病中使用这些化合物和组合物。

  公开号：

  WO2009140163A1

文献信息

• OXAZOLOBENZIMIDAZOLE DERIVATIVES
  申请人：Brnardic Edward J.

  公开号：US20110124661A1

  公开（公告）日：2011-05-26

  The present invention is directed to oxazolobenzimidazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

  本发明涉及氧唑苯并咪唑衍生物，它们是代谢型谷氨酸受体（特别是mGluR2受体）的增强剂，可用于治疗或预防与谷氨酸功能障碍有关的神经和精神障碍以及代谢型谷氨酸受体参与的疾病。本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在预防或治疗代谢型谷氨酸受体参与的疾病方面的使用。
• Discovery of Oxazolobenzimidazoles as Positive Allosteric Modulators for the mGluR2 Receptor
  作者：Robert M. Garbaccio、Edward J. Brnardic、Mark E. Fraley、George D. Hartman、Pete H. Hutson、Julie A. O'Brien、Brian C. Magliaro、Jason M. Uslaner、Sarah L. Huszar、Kerry L. Fillgrove、James H. Small、Cuyue Tang、Yuhsin Kuo、Marlene A. Jacobson

  DOI：10.1021/ml100115a

  日期：2010.11.11

  Novel oxazolobenzimidazoles are described as potent and selective positive allosteric modulators of the metabotropic glutamate receptor 2. The discovery of this class and optimization of its physicial and pharmacokinetic properties led to the identification of potent and orally bioavailable compounds (20 and 21) as advanced leads. Compound 20 (TBPCOB) was shown to have robust activity in a PCP-induced hyperlocomotion model in rat, an assay responsive to clinical antipsychotic treatments for schizophrenia.
• METHOD FOR TREATING SCHIZOPHRENIA AND RELATED DISEASES
  申请人：MELTZER Herbert Y.

  公开号：US20110237602A1

  公开（公告）日：2011-09-29

  The invention relates to a method for treating schizophrenia and/or related diseases comprising administering lurasidone and a mGluR2 ligand to a mammal in need thereof.
• US8735397B2
  申请人：——

  公开号：US8735397B2

  公开（公告）日：2014-05-27
• [EN] OXAZOLOBENZIMIDAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS D'OXAZOLOBENZIMIDAZOLE
  申请人：MERCK & CO INC

  公开号：WO2009140163A1

  公开（公告）日：2009-11-19

  The present invention is directed to oxazolobenzimidazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

  本发明涉及噁唑基苯并咪唑衍生物，它们是代谢型谷氨酸受体的增强剂，特别是mGluR2受体，可用于治疗或预防与谷氨酸功能障碍相关的神经和精神疾病，以及代谢型谷氨酸受体参与的疾病。该发明还涉及包含这些化合物的药物组合物，以及在预防或治疗代谢型谷氨酸受体参与的这类疾病中使用这些化合物和组合物。